Atara, Fujifilm Enter Deal to Produce Cell Therapies
Atara Biotherapeutics has reached an agreement with Fujifilm Diosynth Biotechnologies for the production of its cell therapy pipeline, including…
Articles by Marisa Wexler, MS
How Vitamin D Modulates Immune System Activity Detailed in Study
Vitamin D can influence the immune system’s tolerance to certain proteins by changing how DNA is packaged in specific immune…
Study Explains How Epstein-Barr Virus Infection Could Cause MS
Similarities between an Epstein-Barr virus (EBV) protein and a brain protein called GlialCAM may explain why EBV infection increases the risk…
Imaging Brain Metabolites May Help Diagnose, Monitor MS
A new imaging technique called magnetic resonance spectroscopic imaging, or MRSI, could be useful for diagnosing and monitoring multiple…
Study Probes Why Some Don’t Experience Placebo Effect
Differences in the physical architecture of the brain may explain why some people with multiple sclerosis (MS), but not…
Acthar Gel May Help RRMS Patients Who Fail Corticosteroids
Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis…
High Levels of Gut Bacterial Toxins Found in Spinal Fluid of MS Patients
People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around…
Generics of Gilenya Not Likely in US for at Least Another Two Years
A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for…
New Machine Learning Algorithm Could Help in Diagnosing MS Sooner
A new machine learning algorithm — designed to analyze healthcare records — could help in diagnosing multiple sclerosis (MS)…
Being a Lifelong Musician May Protect Brain From Damage of Aging
Being a lifelong musician can help protect certain tracts of the brain’s white matter from damage during aging, potentially warding…
Top 10 Multiple Sclerosis Stories of 2021
Multiple Sclerosis News Today brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related…
Results From Trial of Simvastatin for SPMS Expected in 2025
MS-STAT2, a clinical trial testing whether the cholesterol-lowering medication simvastatin might slow disability progression in secondary progressive multiple…
Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines
Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to…
Little Evidence Acthar Gel Better Than Cheaper Substitutes: Review
There is minimal evidence that the expensive anti-inflammatory medication Acthar Gel (repository corticotropin injection) is more effective than inexpensive…
Alliance Outlines Global Goals for Progressive MS Research and Care
Leaders of the International Progressive MS Alliance have proposed a global research strategy to find better ways to care for…
Higher Sunlight Exposure Tied to Reduced MS Risk in Children
Children and young adults who spend more time outdoors in the sunshine are less likely to develop multiple sclerosis…
Imaging of Retina Can Help in Monitoring Nerve Cell Damage in MS
An imaging technique called optical coherence tomography (OCT) could be useful for monitoring nervous system damage in people with…
National MS Society Funds 13 New Research Projects
The National MS Society has announced it is funding 13 new research projects that seek to better understand the…
Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in…
Worsening of Disability Evident in Older Patients Who Stop DMTs
While older multiple sclerosis (MS) patients whose conditions are stable commonly stop using disease-modifying therapies (DMTs), a study…
Immune-suppressing Medicines May Reduce COVID-19 Vaccine Efficacy
A class of immune-suppressing medications called TNF-alpha inhibitors can reduce the efficacy of vaccines for COVID-19, according to a study…
Some Cell Therapies Work by Dying, New Research Shows
Certain cell therapies that hold promise for treating autoimmune diseases like multiple sclerosis might work not because of the…
1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS
Immunic Therapeutics has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s…
Cholesterol Made by Nerve Cells Repairs Myelin Damage in Mice
Cholesterol made by neurons is crucial for repairing long-term damage to the myelin sheath, the fatty coating around nerve fibers…
Vumerity Approved for RRMS in European Union
The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting…
sNfL Levels Linked to Relapse-free Disability Progression, Move to SPMS
Measuring levels of the protein serum neurofilament light chain (NfL)Â can help to identify people with relapsing-remitting multiple sclerosis (RRMS)…
Study Sheds Light on How Tecfidera Kills Immune Cells
The multiple sclerosis (MS) treatment Tecfidera (dimethyl fumarate) triggers immune cell death by interacting with a protein called…
Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds
Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including…
Younger Age, Certain Lesions Linked to Higher MS Risk for RIS Patients
Among people with nervous system damage indicative of multiple sclerosis (MS), but who don’t yet have the disease —…
Never Drinking Alcohol Tied to ‘Significantly’ Higher MS Risk
Not drinking alcohol significantly increases the risk of developing multiple sclerosis (MS), especially if a person also is a…